Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY14725 LUNGMAP: A Master Protocol To Evaluate Biomarker Driven Therapies And Immunotherapies In Previously Treated Non Small Cell Lung Cancer (Lung Map Screening Study) This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Study Information
STUDY20133 Pediatric Acute Leukemia (PedAL) Screening Trial Developing New Therapies for Relapsed Leukemias To utilize clinical and biological characteristics of acute leukemias to screen for patient eligibility for available Phase I/II PedAL sub-trials. To maintain a longitudinal and comprehensive registry from relapse in children and young adults with recurrent and refractory leukemia. Study Information
STUDY21784 Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancer The primary objective of this study is to determine the proportion of patients with stage IA2-III lung cancers who possess actionable oncogenic drivers. The screening approach will be considered feasible if, utilizing tumor or plasma assays, 35% of non-squamous non-small cell lung cancers are identified as having a actionable genomic alteration including ALK rearrangements, BRAFV600E mutations, EGFR sensitizing mutations, HER2 mutation, HER2 amplification, MET amplification, MET exon 14 mutation, RET rearrangements, NTRK rearrangement, KRAS G12C, or ROS1 rearrangements Study Information
STUDY22276 Advanced Precision Observational Lung Living Outcomes: Lung Cancer Screening Study The objective of this study is to develop new and/or validate a panel of blood-based biomarkers and candidate classifiers developed by PrognomiQ for lung cancer detection in patients undergoing lung cancer screening. Study Information
STUDY22991 Multi Center Research Evaluation of New Brain Imaging Techniques The primary objective is to perform a multi-site research trial at 3.0 Tesla to characterize the appearance of contrast-enhancing brain tumors with T1RESS, and to determine its accuracy for brain metastases compared to standard-of-care MPRAGE. A secondary objective will be to evaluate the impact of variations in pulse sequence design and scan parameters on image quality and lesion conspicuity. Study Information